Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision / MedCity
Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #healthcarefinance
Saturday, March 14, 2026, 8:21 pm / permalink 20771 / 2 stories in 2 days
‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up / MedCity
Marissa Plescia / medcitynews - Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say.The post ‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up appeared first on MedCity News.
#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #digitalhealth #healthcarefinance #supplychain
Saturday, March 14, 2026, 2:22 pm / permalink 20763 / 3 stories in 2 days
Grail names new CEO as Bob Ragusa retires / Endpoints
Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...
#healthcare #biotech #medicaldevices #oncology #healthcarefinance #cancerresearch
Saturday, March 14, 2026, 4:21 am / permalink 20744 / 5 stories in 2 days
Vanderbilt Health president, CEO to retire / Beckers
Paige Twenter / beckershospitalreview - Jeff Balser, MD, PhD, president and CEO of Vanderbilt Health and dean of Vanderbilt University’s school of medicine, plans to retire from both roles Dec. 31, according to a March 12 news release from the Nashville, Tenn.-based organizations. During his 17…
#healthcare #hospitaloperations #healthcarefinance #researchfunding
Saturday, March 14, 2026, 2:21 am / permalink 20741 / 2 stories in 2 days